Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells

Yoshikazu Tasaki, Tomohiro Omura, Takehiro Yamada, Tomoko Ohkubo, Manabu Suno, Shinya Iida, Tomoki Sakaguchi, Masaru Asari, Keiko Shimizu, Kazuo Matsubara

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by dopaminergic neuronal death in the substantia nigra pars compacta. There is growing interest in the effects of nonsteroidal antiinflammatory drugs (NSAIDs) against PD progression. In this study, we investigated the neuroprotective effect of NSAIDs on neuronal damage induced by 1-methyl-4-phenyl pyridinium (MPP+) in human dopaminergic SH-SY5Y neuroblastoma cells. Of the NSAIDs tested, only meloxicam indicated protective effect on MPP+-induced neurotoxicity in SH-SY5Y cells, although such an effect was not established with indomethacin, ibuprofen and cyclooxygenase (COX)-2 selective inhibitors (NS-398 and CAY-10404). The neuroprotective effect of meloxicam against MPP+ toxicity was specific, as toxicities induced by other cytotoxic agents (such as rotenone, MG-132, tunicamycin and ethacrynic acid) were not attenuated by meloxicam. The neuroprotective effect of meloxicam on MPP+-induced apoptosis was abolished by a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, but not by a MEK inhibitor, PD98059. The Akt phosphorylation levels were predominantly suppressed 4 h after MPP+ incubation (i.e. when the cell toxicity was not apparently observed yet). Meloxicam completely prevented the Akt phosphorylation suppression caused by MPP+ exposure, while meloxicam per se did not promote the Akt phosphorylation. These results strongly suggest that the neuroprotective effect of meloxicam is mediated by the maintenance of cell survival signaling in the PI3K/Akt pathway, but not by COX-2 inhibition. Therefore, meloxicam may have therapeutic potential in preventing development or delaying progress of PD.

Original languageEnglish
Pages (from-to)25-33
Number of pages9
JournalBrain Research
Volume1344
DOIs
Publication statusPublished - Jul 16 2010
Externally publishedYes

Fingerprint

meloxicam
Phosphatidylinositol 3-Kinase
1-Methyl-4-phenylpyridinium
Neuroblastoma
Neuroprotective Agents
Parkinson Disease
Anti-Inflammatory Agents
Phosphorylation
Pharmaceutical Preparations
Ethacrynic Acid
Rotenone
Tunicamycin
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Cyclooxygenase 2 Inhibitors
Ibuprofen
Mitogen-Activated Protein Kinase Kinases
Cytotoxins
Cyclooxygenase 2
Indomethacin
Neurodegenerative Diseases

Keywords

  • Akt
  • Meloxicam
  • MPP
  • Neuroprotection
  • NSAID
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells. / Tasaki, Yoshikazu; Omura, Tomohiro; Yamada, Takehiro; Ohkubo, Tomoko; Suno, Manabu; Iida, Shinya; Sakaguchi, Tomoki; Asari, Masaru; Shimizu, Keiko; Matsubara, Kazuo.

In: Brain Research, Vol. 1344, 16.07.2010, p. 25-33.

Research output: Contribution to journalArticle

Tasaki, Yoshikazu ; Omura, Tomohiro ; Yamada, Takehiro ; Ohkubo, Tomoko ; Suno, Manabu ; Iida, Shinya ; Sakaguchi, Tomoki ; Asari, Masaru ; Shimizu, Keiko ; Matsubara, Kazuo. / Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells. In: Brain Research. 2010 ; Vol. 1344. pp. 25-33.
@article{06134a529800441eae7ae8cccd260bfb,
title = "Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells",
abstract = "Parkinson's disease (PD) is a common neurodegenerative disorder characterized by dopaminergic neuronal death in the substantia nigra pars compacta. There is growing interest in the effects of nonsteroidal antiinflammatory drugs (NSAIDs) against PD progression. In this study, we investigated the neuroprotective effect of NSAIDs on neuronal damage induced by 1-methyl-4-phenyl pyridinium (MPP+) in human dopaminergic SH-SY5Y neuroblastoma cells. Of the NSAIDs tested, only meloxicam indicated protective effect on MPP+-induced neurotoxicity in SH-SY5Y cells, although such an effect was not established with indomethacin, ibuprofen and cyclooxygenase (COX)-2 selective inhibitors (NS-398 and CAY-10404). The neuroprotective effect of meloxicam against MPP+ toxicity was specific, as toxicities induced by other cytotoxic agents (such as rotenone, MG-132, tunicamycin and ethacrynic acid) were not attenuated by meloxicam. The neuroprotective effect of meloxicam on MPP+-induced apoptosis was abolished by a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, but not by a MEK inhibitor, PD98059. The Akt phosphorylation levels were predominantly suppressed 4 h after MPP+ incubation (i.e. when the cell toxicity was not apparently observed yet). Meloxicam completely prevented the Akt phosphorylation suppression caused by MPP+ exposure, while meloxicam per se did not promote the Akt phosphorylation. These results strongly suggest that the neuroprotective effect of meloxicam is mediated by the maintenance of cell survival signaling in the PI3K/Akt pathway, but not by COX-2 inhibition. Therefore, meloxicam may have therapeutic potential in preventing development or delaying progress of PD.",
keywords = "Akt, Meloxicam, MPP, Neuroprotection, NSAID, Parkinson's disease",
author = "Yoshikazu Tasaki and Tomohiro Omura and Takehiro Yamada and Tomoko Ohkubo and Manabu Suno and Shinya Iida and Tomoki Sakaguchi and Masaru Asari and Keiko Shimizu and Kazuo Matsubara",
year = "2010",
month = "7",
day = "16",
doi = "10.1016/j.brainres.2010.04.085",
language = "English",
volume = "1344",
pages = "25--33",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells

AU - Tasaki, Yoshikazu

AU - Omura, Tomohiro

AU - Yamada, Takehiro

AU - Ohkubo, Tomoko

AU - Suno, Manabu

AU - Iida, Shinya

AU - Sakaguchi, Tomoki

AU - Asari, Masaru

AU - Shimizu, Keiko

AU - Matsubara, Kazuo

PY - 2010/7/16

Y1 - 2010/7/16

N2 - Parkinson's disease (PD) is a common neurodegenerative disorder characterized by dopaminergic neuronal death in the substantia nigra pars compacta. There is growing interest in the effects of nonsteroidal antiinflammatory drugs (NSAIDs) against PD progression. In this study, we investigated the neuroprotective effect of NSAIDs on neuronal damage induced by 1-methyl-4-phenyl pyridinium (MPP+) in human dopaminergic SH-SY5Y neuroblastoma cells. Of the NSAIDs tested, only meloxicam indicated protective effect on MPP+-induced neurotoxicity in SH-SY5Y cells, although such an effect was not established with indomethacin, ibuprofen and cyclooxygenase (COX)-2 selective inhibitors (NS-398 and CAY-10404). The neuroprotective effect of meloxicam against MPP+ toxicity was specific, as toxicities induced by other cytotoxic agents (such as rotenone, MG-132, tunicamycin and ethacrynic acid) were not attenuated by meloxicam. The neuroprotective effect of meloxicam on MPP+-induced apoptosis was abolished by a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, but not by a MEK inhibitor, PD98059. The Akt phosphorylation levels were predominantly suppressed 4 h after MPP+ incubation (i.e. when the cell toxicity was not apparently observed yet). Meloxicam completely prevented the Akt phosphorylation suppression caused by MPP+ exposure, while meloxicam per se did not promote the Akt phosphorylation. These results strongly suggest that the neuroprotective effect of meloxicam is mediated by the maintenance of cell survival signaling in the PI3K/Akt pathway, but not by COX-2 inhibition. Therefore, meloxicam may have therapeutic potential in preventing development or delaying progress of PD.

AB - Parkinson's disease (PD) is a common neurodegenerative disorder characterized by dopaminergic neuronal death in the substantia nigra pars compacta. There is growing interest in the effects of nonsteroidal antiinflammatory drugs (NSAIDs) against PD progression. In this study, we investigated the neuroprotective effect of NSAIDs on neuronal damage induced by 1-methyl-4-phenyl pyridinium (MPP+) in human dopaminergic SH-SY5Y neuroblastoma cells. Of the NSAIDs tested, only meloxicam indicated protective effect on MPP+-induced neurotoxicity in SH-SY5Y cells, although such an effect was not established with indomethacin, ibuprofen and cyclooxygenase (COX)-2 selective inhibitors (NS-398 and CAY-10404). The neuroprotective effect of meloxicam against MPP+ toxicity was specific, as toxicities induced by other cytotoxic agents (such as rotenone, MG-132, tunicamycin and ethacrynic acid) were not attenuated by meloxicam. The neuroprotective effect of meloxicam on MPP+-induced apoptosis was abolished by a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, but not by a MEK inhibitor, PD98059. The Akt phosphorylation levels were predominantly suppressed 4 h after MPP+ incubation (i.e. when the cell toxicity was not apparently observed yet). Meloxicam completely prevented the Akt phosphorylation suppression caused by MPP+ exposure, while meloxicam per se did not promote the Akt phosphorylation. These results strongly suggest that the neuroprotective effect of meloxicam is mediated by the maintenance of cell survival signaling in the PI3K/Akt pathway, but not by COX-2 inhibition. Therefore, meloxicam may have therapeutic potential in preventing development or delaying progress of PD.

KW - Akt

KW - Meloxicam

KW - MPP

KW - Neuroprotection

KW - NSAID

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=77953912213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953912213&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2010.04.085

DO - 10.1016/j.brainres.2010.04.085

M3 - Article

C2 - 20452332

AN - SCOPUS:77953912213

VL - 1344

SP - 25

EP - 33

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -